The CEO leaves Redsense Medical AB

The Board of Directors of Redsense Medical AB and Pontus Nobréus, CEO since Aug 2022, have reached a mutual agreement that Pontus Nobréus will leave his position as CEO. The board of Redsense has appointed the current CFO, Jennie Kardell, as acting CEO. The board would like to express its thanks to Pontus Nobréus for the two years he has led the company.

Work on recruiting a new CEO will begin immediately.

Redsense Medical AB

The Board of Directors

Contact information

For more information, please contact: 
Eva Walde (Chairman of the board)
Telephone: +46 708 680 582
E-mail: waldeeva@gmail.com

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.